A Phase 4 interventional study of Placebo Capsules + Placebo Patch and Placebo capsules + Lidoderm® in Postherpetic Neuralgia, Diabetic Neuropathy and Complex Regional Pain Syndrome, sponsored by Endo Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-02.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Neuralgia, Postherpetic with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Neuralgia, Postherpetic · United States.
Among the 60 studies in Neuralgia, Postherpetic with a site in United States, this one is the 33rd largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2003, is one of 4 in phase 4, and was the 28th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →4 of the 60 studies in Neuralgia, Postherpetic with a site in United States are open now. Recruiting first, the newest first:
Brown University · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 22–80
University of Minnesota · Sites in United States
Ages 22+
Neurodawn Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–45 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 35 · Phase 3 9 · Phase 4 4
First in 1993; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 93 across the 56 interventional studies, 201 across the 3 observational. Of the 51 that completed or were terminated, 22 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 2 studies filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
1 of the studies in Neuralgia, Postherpetic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 60 studies in Neuralgia, Postherpetic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a Phase IV clinical trial to assess the comparative efficacy and safety of Lidoderm monotherapy versus gabapentin monotherapy in treating a diverse group of peripheral neuropathic pain patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
Drug: Placebo Capsules + Placebo Patch
Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
Drug: Placebo capsules + Lidoderm®
Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
Drug: Gabapentin + Placebo · Drug: Gabapentin 300 mg capsules 1800 mg/day + placebo patch
Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
Drug: Gabapentin + Lidoderm® · Drug: Gabapentin 1800 mg/day + Lidoderm patch
Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Also known as: Lidocaine patch 5%
Drug page: Lidoderm
Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Also known as: Lidocaine patch 5%
Drug page: Lidoderm
Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Also known as: Lidocaine patch 5%
Drug pages: Gabapentin · Lidoderm
Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Also known as: Lidocaine patch 5%
Gabapentin 300 mg capsules 1800 mg/day + placebo patch
Drug page: Gabapentin
Average daily pain intensity (BPI Questions 3,4,5, and 6)
Time frame: Visit - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 21), V6 (Day 28), V7/EOS (Day 35)
Pain Quality Assessment Scale (PQAS)
Investigator and Patient Global Impression of Change
Allodynia Testing
QoL; Symptom Checklist, pain interference with QoL
Patient Global Impression of Treatment Satisfaction, disability assessment, and Percent Pain Relief (BPI Question 8)
Safety assessments include adverse events; dermal assessments/sensory testing, clinical laboratory tests, vital sign measurements and physical/neurological examination
The record gives a start of Jan 2003 and a primary completion of Jun 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidoderm